

Tesamorelin Dosing Chart

A GHRH analog approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Commonly discussed doses: 1 mg–2 mg. The approved product carries its own labeled dose and reconstitution instructions — follow those, not a general calculator.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

FDA-approved as Egrifta for HIV-associated lipodystrophy. Use for any other purpose is off-label and requires a prescribing clinician's judgment.

1 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	1 mg	2 mg
1 mL	1	100 u	—
2 mL	0.5	—	—
3 mL	0.33	—	—

2 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	1 mg	2 mg
1 mL	2	50 u	100 u
2 mL	1	100 u	—
3 mL	0.67	—	—

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/tesamorelin

Tesamorelin dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.